A Phase 2 interventional study of Brentuximab Vedotin in Hodgkin Disease and Lymphoma, Large-Cell, Anaplastic, sponsored by Takeda. Completed at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-24.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 53rd largest by enrollment, is one of 6 that started in 2016, is one of 41 in phase 2, and was the 49th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18–60
Children's Cancer Group, China · Sites in China
Ages 2–35
Takeda · Sites in India
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 56 · Phase 3 11 · Phase 4 2
First in 2006; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is close to the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 80 interventional studies. Of the 46 that completed or were terminated, 26 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 80 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Hodgkin Disease by Takeda: 3 open now, 4 under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 15 studies in Hodgkin Disease by Takeda, this one is the only one that started in 2016, is the only one in phase 2, and was the 7th registered.
Takeda’s Hodgkin Disease studies by the year they started, since 1997.
7 of the studies testing Brentuximab Vedotin in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05180097Canadian Cancer Trials GroupPembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | 2026-12-31 |
| NCT03755804St. Jude Children's Research HospitalPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | 2027-01-01 |
| NCT06377566Memorial Sloan Kettering Cancer CenterA Study of BV-AVD in People With Bulky Hodgkin Lymphoma | 2027-04 |
| NCT04561206City of Hope Medical CenterBrentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2027-10-02 |
| NCT05404945University of VirginiaFitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | 2027-10-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, from their registry updates:
Among Takeda’s 15 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of brentuximab vedotin as a single agent in Chinese participants with relapsed/refractory CD30+ Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL).
The drug being tested in this study is called brentuximab vedotin. This study will look at efficacy, safety and PK of brentuximab vedotin in Chinese participants with relapsed/refractory CD30+ HL or sALCL.
The study will enroll approximately 30 patients. Participants will receive:
All participants will be administered IV infusion on Day 1 each 3-week cycle until the sooner of disease progression, unacceptable toxicity, or completion of 16 cycles.
This multi-center trial will be conducted in China only. The overall time to participate in this study is 3.5 years. Participants will make multiple visits to the clinic, and will be followed for overall survival (OS) every 12 weeks until death, withdrawal of consent, 18 months after end of treatment (EOT) or study closure, whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have the following required screening laboratory data. Participants must not have received recombinant granulocyte-colony stimulating factor (G-CSF) or transfusion within 1 week before the screening hematology assessment.
Exclusion Criteria:
With a history of another that has not been in remission for at least 3 years. The following are exempt from the 3-year limit:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion on Day 1 of each 3-week cycle until the sooner of disease progression, unacceptable toxicity, or completion of 16 cycles.
Drug: Brentuximab Vedotin
Brentuximab vedotin IV infusion
Overall Response Rate (ORR)
ORR is defined as the percentage of participants who have achieved complete remission (CR)=disappearance of all evidence of disease or partial remission (PR)=regression of greater than or equal to 50% of measurable disease and no new site by end of treatment (EOT) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
Time frame: Baseline, at Cycles (each cycle was of 3 weeks) 2, 4, 7, 10, 13, and 16 during treatment until disease progression death or end of treatment (approximately 12 months)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs or worsens after receiving study drug.
Time frame: First dose of study drug up to 30 days after last dose of study drug (approximately 12 months)
Number of Participants With Abnormal Clinical Laboratory Findings Reported as Adverse Events
Clinical Laboratory tests included tests of Chemistry, Hematology and Urinalysis prespecified in the protocol. Abnormal laboratory values assessed by the investigator that lead to discontinuation or delay in treatment, dose modification, therapeutic intervention, or were considered by the investigator to be clinically significant changes from Baseline were recorded as Adverse Events. Neutropenia (pooled) includes preferred terms Neutropenia and Neutrophil count decreased.
Time frame: First dose of study drug up to 30 days after last dose of study drug (approximately 12 months)
Number of Participants With Abnormal Vital Signs Reported as Adverse Events
Vital signs included blood pressure in the sitting position, pulse rate, axillary temperature and weight. Abnormal vital sign values considered by the investigator to be clinically significant were recorded as Adverse Events.
Time frame: First dose of study drug up to 30 days after last dose of study drug (approximately 12 months)
Complete Remission (CR) Rate
CR rate is defined as the percentage of participants who have achieved CR by EOT. CR is defined as disappearance of all evidence of disease per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
Time frame: Baseline, at Cycles (each cycle was of 3 weeks) 2, 4, 7, 10, 13, and 16 during treatment, and every 12 weeks during PFS follow-up period, until disease progression death or end of treatment (approximately 12 months)
Duration of Response (DOR)
DOR is defined as the time between the first documentation of objective tumor response (CR or PR) and the first subsequent documentation of objective tumor progression or death due to any cause, whichever occurs first. CR is defined as disappearance of all evidence of disease. PR is defined as regression of greater than or equal to 50% of measurable disease and no new sites.
Time frame: Up to 3.2 years
Progression Free Survival (PFS)
PFS is defined as the time from the start of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.
Time frame: Up to 3.2 years
Overall Survival (OS)
Overall survival is defined as the time from the start of treatment to the date of death.
Time frame: Up to 3.2 years
B Symptom Resolution Rate
B Symptom Resolution Rate is defined as the percentage of participants with lymphoma-related symptoms (B symptoms: fever, night sweats, or weight loss \>10%) at baseline who achieved resolution of all B symptoms at any time during the treatment period.
Time frame: Day 1 of each cycle (each cycle was of 3 weeks) up to 30 days after last dose of study drug (approximately 12 months)
Cmax: Maximum Observed Serum Concentration for Brentuximab Vedotin Antibody-drug Conjugate (ADC)
Time frame: Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Cmax: Maximum Observed Serum Concentration for Total Antibody (TAb)
Time frame: Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Cmax: Maximum Observed Plasma Concentration for Monomethyl Auristatin E (MMAE)
Time frame: Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Brentuximab Vedotin ADC
Time frame: Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for TAb
Time frame: Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MMAE
Time frame: Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
AUC(0-∞): Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC
Time frame: Cycle (each cycle was of 3 weeks) 1: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
AUC(0-∞): Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAb
Time frame: Cycle (each cycle was of 3 weeks) 1: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
AUC(0-∞): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MMAE
Time frame: Cycle (each cycle was of 3 weeks) 1: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Number of Participants With Antitherapeutic Antibodies (ATA) and Neutralizing Antitherapeutic Antibodies (nATA) to Brentuximab Vedotin
Blood samples were collected to assess the immunogenicity of brentuximab vedotin (ATA development) using a laboratory test to determine ATA titers. Confirmed ATA-positive response was categorized as transient (defined as 1 or 2 post-baseline confirmed ATA-positive responses) and persistent (defined as more than 2 post-baseline confirmed ATA positive responses) and by nATA status. The number of participants in each baseline ATA and post-baseline ATA categories are reported.
Time frame: Baseline, at Cycles (each cycle was of 3 weeks) 2, 4, 7, 10, 13, and 16 during treatment until disease progression, death or end of treatment (approximately 12 months)
Participants took part in the study at 7 investigative sites in China. The study was conducted from 07 November 2016 to 3 February 2020.
| Milestone | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) |
|---|---|---|
| Started | 30 | 9 |
| Completed | 25 | 6 |
| Not completed | 5 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 4 | 3 |
ORR is defined as the percentage of participants who have achieved complete remission (CR)=disappearance of all evidence of disease or partial remission (PR)=regression of greater than or equal to 50% of measurable disease and no new site by end of treatment (EOT) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
| percentage of participants | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) |
|---|---|---|
| Overall Response Rate (ORR) | 70.0 (50.60 to 85.27) | 66.7 (29.93 to 92.51) |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs or worsens after receiving study drug.
| Participants | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 30 | 9 |
Clinical Laboratory tests included tests of Chemistry, Hematology and Urinalysis prespecified in the protocol. Abnormal laboratory values assessed by the investigator that lead to discontinuation or delay in treatment, dose modification, therapeutic intervention, or were considered by the investigator to be clinically significant changes from Baseline were recorded as Adverse Events. Neutropenia (pooled) includes preferred terms Neutropenia and Neutrophil count decreased.
| Participants | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) |
|---|---|---|
| Alanine aminotransferase increased | 18 | 6 |
| Aspartate aminotransferase increased | 17 | 6 |
| Gamma-glutamyltransferase increased | 3 | 4 |
| Blood bilirubin increased | 0 | 2 |
| Reticulocyte count decreased | 9 | 2 |
| Reticulocyte count increased | 6 | 1 |
| Haemoglobin decreased | 1 | 1 |
| Reticulocyte percentage increased | 1 | 0 |
| White blood cell count decreased | 4 | 3 |
| Lymphocyte count decreased | 5 | 0 |
| Lymphocyte percentage decreased | 2 | 0 |
| Lymphocyte count increased | 0 | 1 |
| Lymphocyte percentage increased | 0 | 1 |
| Monocyte count increased | 0 | 1 |
| Neutrophil count increased | 0 | 1 |
| Neutrophil percentage decreased | 1 | 0 |
| White blood cell count increased | 0 | 1 |
| Platelet count decreased | 2 | 2 |
| Blood uric acid increased | 2 | 1 |
| Blood glucose increased | 1 | 1 |
| Blood albumin decreased | 0 | 1 |
| Protein total decreased | 0 | 1 |
| Blood creatinine increased | 1 | 1 |
| Blood urea decreased | 0 | 1 |
| Blood urea increased | 0 | 1 |
| Blood lactate dehydrogenase increased | 0 | 2 |
| Blood alkaline phosphatase increased | 0 | 1 |
| Blood cholesterol increased | 0 | 1 |
| Blood calcium decreased | 0 | 1 |
| Blood calcium increased | 0 | 1 |
| Blood chloride decreased | 0 | 1 |
| Blood phosphorus decreased | 0 | 1 |
| Blood potassium decreased | 0 | 1 |
| Blood triglycerides increased | 0 | 1 |
| Glucose urine present | 1 | 0 |
| Leukopenia | 15 | 2 |
| Anaemia | 12 | 3 |
| Hyperuricaemia | 4 | 2 |
| Hypertriglyceridaemia | 2 | 2 |
| Hypokalaemia | 3 | 2 |
| Blood creatine phosphokinase increased | 1 | 1 |
| Total bile acids increased | 0 | 2 |
| Alpha hydroxybutyrate dehydrogenase increased | 0 | 1 |
| Blood magnesium decreased | 0 | 1 |
| High density lipoprotein decreased | 0 | 1 |
| Hypercalcaemia | 0 | 1 |
| Hyperglycaemia | 1 | 0 |
| Hypoalbuminaemia | 0 | 1 |
| Hypocalcaemia | 0 | 1 |
| Hyponatraemia | 1 | 0 |
| Lipoprotein (a) increased | 0 | 1 |
| Low density lipoprotein increased | 0 | 1 |
| Monocytosis | 0 | 1 |
| Red blood cell sedimentation rate increased | 1 | 0 |
| Thrombocytopenia | 1 | 0 |
| Neutropenia (Pooled) | 19 | 5 |
Vital signs included blood pressure in the sitting position, pulse rate, axillary temperature and weight. Abnormal vital sign values considered by the investigator to be clinically significant were recorded as Adverse Events.
| Participants | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) |
|---|---|---|
| Weight increased | 4 | 2 |
| Weight decreased | 1 | 2 |
CR rate is defined as the percentage of participants who have achieved CR by EOT. CR is defined as disappearance of all evidence of disease per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
| percentage of participants | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) |
|---|---|---|
| Complete Remission (CR) Rate | 20.0 (7.71 to 38.57) | 55.6 (21.20 to 86.30) |
DOR is defined as the time between the first documentation of objective tumor response (CR or PR) and the first subsequent documentation of objective tumor progression or death due to any cause, whichever occurs first. CR is defined as disappearance of all evidence of disease. PR is defined as regression of greater than or equal to 50% of measurable disease and no new sites.
| months | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) |
|---|---|---|
| Duration of Response (DOR) | 12.0 (4.37 to NA) | NA (1.41 to NA) |
PFS is defined as the time from the start of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.
| months | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) |
|---|---|---|
| Progression Free Survival (PFS) | 13.5 (6.77 to 17.81) | 23.2 (1.25 to NA) |
Overall survival is defined as the time from the start of treatment to the date of death.
| months | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (3.19 to NA) |
B Symptom Resolution Rate is defined as the percentage of participants with lymphoma-related symptoms (B symptoms: fever, night sweats, or weight loss \>10%) at baseline who achieved resolution of all B symptoms at any time during the treatment period.
| percentage of participants | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) |
|---|---|---|
| B Symptom Resolution Rate | 50.0 (1.26 to 98.74) | 100.00 (15.81 to 100.00) |
| micrograms/milliliter (ug/mL) | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Cycle 1 | 36.9504 ± 9.90360 |
| Cycle 2 | 32.4341 ± 5.83197 |
| ug/mL | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Cycle 1 | 38.2293 ± 7.95483 |
| Cycle 2 | 39.9859 ± 12.43445 |
| ug/mL | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Cycle 1 | 5.1623 ± 3.69893 |
| Cycle 2 | 3.6218 ± 2.89331 |
| days | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Cycle 1 | 0.0576 (0.031 to 0.221) |
| Cycle 2 | 0.0528 (0.028 to 0.214) |
| days | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Cycle 1 | 0.0653 (0.031 to 1.067) |
| Cycle 2 | 0.0660 (0.028 to 0.972) |
| days | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| Cycle 1 | 2.0729 (1.031 to 6.991) |
| Cycle 2 | 2.9785 (0.178 to 6.986) |
| day*ug/mL | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| AUC(0-∞): Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC | 79.9951 ± 19.59116 |
| day*ug/mL | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| AUC(0-∞): Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAb | 168.6618 ± 41.62840 |
| day*ug/mL | Brentuximab Vedotin 1.8 mg/kg |
|---|---|
| AUC(0-∞): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MMAE | 36.8625 ± 22.79816 |
Blood samples were collected to assess the immunogenicity of brentuximab vedotin (ATA development) using a laboratory test to determine ATA titers. Confirmed ATA-positive response was categorized as transient (defined as 1 or 2 post-baseline confirmed ATA-positive responses) and persistent (defined as more than 2 post-baseline confirmed ATA positive responses) and by nATA status. The number of participants in each baseline ATA and post-baseline ATA categories are reported.
| Participants | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) |
|---|---|---|
| Baseline ATA Negative | 29 | 9 |
| Baseline ATA Negative, ATA Negative | 21 | 8 |
| Baseline ATA Negative, Transiently ATA Positive | 7 | 1 |
| Baseline ATA Negative, Persistently ATA Positive | 1 | 0 |
| Baseline ATA Negative, nATA Negative | 0 | 0 |
| Baseline ATA Negative, nATA Positive | 8 | 1 |
| Baseline ATA Positive | 1 | 0 |
| Baseline ATA Positive, ATA Negative | 0 | — |
| Baseline ATA Positive, Transiently ATA Positive | 0 | — |
| Baseline ATA Positive, Persistently ATA Positive | 1 | — |
| Baseline ATA Positive, nATA Negative | 0 | — |
| Baseline ATA Positive, nATA Positive | 1 | — |
Collected over All-Cause Mortality: up to 3.2 years; Serious and Other Adverse Events: First dose of study drug up to 30 days post last dose of study drug (up to 12 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brentuximab Vedotin 1.8 mg/kg (HL) | 4/30 (13.3%) | 1/30 (3.3%) | 30/30 (100%) |
| Brentuximab Vedotin 1.8 mg/kg (sALCL) | 3/9 (33.3%) | 1/9 (11.1%) | 9/9 (100%) |
| Event | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) |
|---|---|---|
| Large intestine polypGastrointestinal disorders | 0/30 | 1/9 |
| Lung infectionInfections and infestations | 1/30 | 0/9 |
| Event | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 18/30 | 6/9 |
| Aspartate aminotransferase increasedInvestigations | 17/30 | 6/9 |
| NeutropeniaBlood and lymphatic system disorders | 19/30 | 5/9 |
| LeukopeniaBlood and lymphatic system disorders | 15/30 | 2/9 |
| Gamma-glutamyltransferase increasedInvestigations | 3/30 | 4/9 |
| PyrexiaGeneral disorders | 6/30 | 4/9 |
| AnaemiaBlood and lymphatic system disorders | 12/30 | 3/9 |
| White blood cell count decreasedInvestigations | 4/30 | 3/9 |
| DiarrhoeaGastrointestinal disorders | 8/30 | 3/9 |
| Reticulocyte count decreasedInvestigations | 9/30 | 2/9 |
Safety Population included all participants who had measurable lesions at baseline and received at least 1 dose of brentuximab vedotin.
| Age, Continuous(years) | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) | Total |
|---|---|---|---|
| Mean | 31.9 ± 8.91 | 41.1 ± 15.28 | 34.0 ± 11.19 |
| Sex: Female, Male(Participants) | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) | Total |
|---|---|---|---|
| Female | 13 | 2 | 15 |
| Male | 17 | 7 | 24 |
| Race/Ethnicity, Customized(Participants) | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) | Total |
|---|---|---|---|
| Ethnicity — Not Hispanic or Latino | 30 | 9 | 39 |
| Race/Ethnicity, Customized(Participants) | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) | Total |
|---|---|---|---|
| Race — Asian | 30 | 9 | 39 |
| Region of Enrollment(Participants) | Brentuximab Vedotin 1.8 mg/kg (HL) | Brentuximab Vedotin 1.8 mg/kg (sALCL) | Total |
|---|---|---|---|
| China | 30 | 9 | 39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2016 to primary completion in Aug 2018, 20 months.
Results were first posted in Sep 2019, 1 year 1 month after primary completion.
Of 206 phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 111. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin